Copper-bound GHK copper tripeptide works at a molecular level primarily by binding copper ions into a stable complex that regulates gene expression, modulates protein synthesis, and influences key cell signalling pathways and biochemical processes. The tripeptide glycyl-L-histidyl-L-lysine exhibits a high affinity for copper, and this binding allows for the controlled delivery and utilisation of copper in biological systems, which is significant for numerous enzymatic and regulatory processes.
At the molecular level, copper-bound GHK has been shown to influence gene expression patterns, including restoring more normal states of genes associated with ageing or diseases. Data from Connectivity Map analyses suggest it interacts with genes related to neuronal health and the general maintenance of cellular functions. This regulatory role is linked to a further impact on protein synthesis, where copper-bound GHK enhances the production of structural and functional proteins such as collagen, elastin, procollagen type I, collagen IV, fibronectin-1, and tropoelastin. These changes reflect its ability to modulate transcriptional and translational activity within cells.
Copper-related GHK also interacts with molecular signalling systems by increasing the levels of growth factors, such as vascular endothelial growth factor, fibroblast growth factor, and nerve growth factor. These signalling molecules are associated with cell communication and coordinated biological responses. Simultaneously, it affects cell cycle regulators like CDK4 and cyclin D1, and increases the levels of markers such as proliferating cell nuclear antigen and p63, indicating modulation of molecular processes linked to cell proliferation. The peptide also enhances the expression of integrins, which play a role in cell adhesion and intracellular signalling pathways.
In a biochemical context, copper-bound GHK participates in mechanisms related to redox reactions by reducing reactive oxygen species levels and increasing antioxidant enzyme activity, such as superoxide dismutase, while simultaneously lowering oxidative stress markers like nitrotyrosine. It also affects inflammatory signalling at a molecular level by reducing markers such as MCP-1 and other pro-inflammatory cytokines. Additionally, it influences the extracellular matrix composition by increasing levels of glycosaminoglycans, dermatan sulphate, and chondroitin sulphate, with dose-dependent effects observed at very low concentrations in vitro.
Further molecular activity includes modulation of signalling pathways such as PI3K/AKT, and enhancement of SIRT1 activity, as well as the ability to inhibit or reverse protein aggregation under specific conditions and reduce metal-induced toxicity. These mechanisms stem from in vitro and animal studies, and their translation to human systems remains limited due to variability in study designs and experimental models.
In the context of research and laboratory applications, copper-GHK is typically used as a copper-bound peptide complex, and its molecular activity is assessed under controlled conditions, with specific concentrations and delivery systems. These results reflect experimental observations and should be interpreted within the scope of laboratory studies, without assuming direct clinical effects.